Tags

Type your tag names separated by a space and hit enter

Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Breast Cancer Res. 2008; 10(5):R79.BC

Abstract

INTRODUCTION

We have previously reported that tumour-specific expression of the rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), in the mevalonate pathway is associated with more favourable tumour parameters in breast cancer. In the present study, we examined the prognostic value of HMG-CoAR expression in a large cohort of primary breast cancer patients with long-term follow up.

METHODS

The expression of HMG-CoAR was assessed by immunohistochemistry on tissue microarrays with tumour specimens from 498 consecutive cases of breast cancer with a median follow-up of 128 months. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the rate of recurrence-free survival (RFS) and breast cancer specific survival (BCSS).

RESULTS

In line with our previous findings, tumour-specific HMG-CoAR expression was associated with low grade (p < 0.001), small size (p = 0.007), oestrogen receptor (ER) positive (p = 0.01), low Ki-67 (p = 0.02) tumours. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS, even when adjusted for established prognostic factors (relative risk [RR] = 0.60, 95% confidence interval [CI] 0.40 to 0.92; p = 0.02). In ER-negative tumours, however, there was a trend, that was not significantly significant, towards a shorter RFS in HMG-CoAR expressing tumours.

CONCLUSIONS

HMG-CoAR expression is an independent predictor of a prolonged RFS in primary breast cancer. This may, however, not be true for ER-negative tumours. Further studies are needed to shed light on the value of HMG-CoAR expression as a surrogate marker of response to statin treatment, especially with respect to hormone receptor status.

Authors+Show Affiliations

Center for Molecular Pathology, Department of Laboratory Medicine, Malmö University Hospital, Lund University, Malmö, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18808688

Citation

Borgquist, Signe, et al. "Prognostic Impact of Tumour-specific HMG-CoA Reductase Expression in Primary Breast Cancer." Breast Cancer Research : BCR, vol. 10, no. 5, 2008, pp. R79.
Borgquist S, Jögi A, Pontén F, et al. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res. 2008;10(5):R79.
Borgquist, S., Jögi, A., Pontén, F., Rydén, L., Brennan, D. J., & Jirström, K. (2008). Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Research : BCR, 10(5), R79. https://doi.org/10.1186/bcr2146
Borgquist S, et al. Prognostic Impact of Tumour-specific HMG-CoA Reductase Expression in Primary Breast Cancer. Breast Cancer Res. 2008;10(5):R79. PubMed PMID: 18808688.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. AU - Borgquist,Signe, AU - Jögi,Annika, AU - Pontén,Fredrik, AU - Rydén,Lisa, AU - Brennan,Donal J, AU - Jirström,Karin, Y1 - 2008/09/22/ PY - 2008/07/22/received PY - 2008/09/17/revised PY - 2008/09/22/accepted PY - 2008/9/24/pubmed PY - 2009/2/6/medline PY - 2008/9/24/entrez SP - R79 EP - R79 JF - Breast cancer research : BCR JO - Breast Cancer Res VL - 10 IS - 5 N2 - INTRODUCTION: We have previously reported that tumour-specific expression of the rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), in the mevalonate pathway is associated with more favourable tumour parameters in breast cancer. In the present study, we examined the prognostic value of HMG-CoAR expression in a large cohort of primary breast cancer patients with long-term follow up. METHODS: The expression of HMG-CoAR was assessed by immunohistochemistry on tissue microarrays with tumour specimens from 498 consecutive cases of breast cancer with a median follow-up of 128 months. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the rate of recurrence-free survival (RFS) and breast cancer specific survival (BCSS). RESULTS: In line with our previous findings, tumour-specific HMG-CoAR expression was associated with low grade (p < 0.001), small size (p = 0.007), oestrogen receptor (ER) positive (p = 0.01), low Ki-67 (p = 0.02) tumours. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS, even when adjusted for established prognostic factors (relative risk [RR] = 0.60, 95% confidence interval [CI] 0.40 to 0.92; p = 0.02). In ER-negative tumours, however, there was a trend, that was not significantly significant, towards a shorter RFS in HMG-CoAR expressing tumours. CONCLUSIONS: HMG-CoAR expression is an independent predictor of a prolonged RFS in primary breast cancer. This may, however, not be true for ER-negative tumours. Further studies are needed to shed light on the value of HMG-CoAR expression as a surrogate marker of response to statin treatment, especially with respect to hormone receptor status. SN - 1465-542X UR - https://www.unboundmedicine.com/medline/citation/18808688/Prognostic_impact_of_tumour_specific_HMG_CoA_reductase_expression_in_primary_breast_cancer_ L2 - https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2146 DB - PRIME DP - Unbound Medicine ER -